NeuroBo Pharmaceuticals News

NeuroBo Pharmaceuticals | 10-Q: Quarterly report

May 9 09:02 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9 08:07 ET

NeuroBo Pharmaceuticals | ARS: Annual Report to Security Holders

Apr 30 08:45 ET

NeuroBo Pharmaceuticals | DEF 14A: Definitive information statements

Apr 30 08:45 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Apr 30 08:35 ET

NeuroBo Pharmaceuticals | EFFECT: Others

Apr 24 06:08 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 17 08:34 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Apr 16 16:36 ET

NeuroBo Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Apr 12 16:09 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Apr 1 08:31 ET

NeuroBo Pharmaceuticals | 10-K: Annual report

Mar 28 22:26 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 28 08:05 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 13 08:33 ET

NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Woodworth Marshall H

Mar 4 21:21 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Mar 4 07:35 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 29 08:33 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Feb 14 08:56 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Feb 1 08:31 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash

Jan 18 00:00 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 9 00:00 ET